Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
You may also be interested in...
Hemispherx Ampligen Filing Will Jumpstart NDA Clock
Biopharma accelerates evaluation of the Toll-like receptor-3 agonist as an adjuvant for HIV/AIDS and avian influenza vaccines.
Hemispherx Ampligen Filing Will Jumpstart NDA Clock
Biopharma accelerates evaluation of the Toll-like receptor-3 agonist as an adjuvant for HIV/AIDS and avian influenza vaccines.
Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia
Company has said it believes indication could add $1 billion in incremental Lyrica sales.